William C Olson
Principal investigator.
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2000First federal award
$16.2MFederal grants as PI23 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
23 awards · $16.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| May 1, 2011 | NIH | NIH R01 PA-50/PA-41 antitoxin antibody therapy for C. difficile infection | $1.1M | PROGENICS PHARMACEUTICALS INC |
| May 1, 2011 | NIH | NIH R01 PA-50/PA-41 antitoxin antibody therapy for C. difficile infection | $1.1M | PROGENICS PHARMACEUTICALS INC |
| Sep 27, 2010 | NIH | NIH U19 HIV-1 Therapy with CCR5 mAB PRO 140-Overview | $415K | PROGENICS PHARMACEUTICALS INC |
| Jul 18, 2009 | NIH | NIH U19 HIV-1 Therapy with CCR5 mAB PRO 140-Overview | $581K | PROGENICS PHARMACEUTICALS INC |
| Jun 15, 2009 | NIH | NIH P01 Structure and Immunogenicity of Cleaved, Stabilized HIV-1 Envelope Trimers | $2.9M | PROGENICS PHARMACEUTICALS INC |
| Jun 15, 2009 | NIH | NIH P01 Structure and Immunogenicity of Cleaved, Stabilized HIV-1 Envelope Trimers | $142K | PROGENICS PHARMACEUTICALS INC |
| May 1, 2007 | NIH | SBIR/STTR Phase I Broadly Neutralizing MAbs against Hepatitis C Virus | $351K | PROGENICS PHARMACEUTICALS INC |
| May 1, 2007 | NIH | SBIR/STTR Phase I Broadly Neutralizing MAbs against Hepatitis C Virus | $287K | PROGENICS PHARMACEUTICALS INC |
| Aug 1, 2004 | NIH | SBIR/STTR Phase I PRO 542 Immunotherapy of Advanced HIV 1 Disease | $300K | PROGENICS PHARMACEUTICALS INC |
| Aug 1, 2004 | NIH | SBIR/STTR Phase I PRO 542 Immunotherapy of Advanced HIV 1 Disease | $291K | PROGENICS PHARMACEUTICALS INC |
| Sep 30, 2002 | NIH | SBIR/STTR Phase II PSMA-VRP vaccine for prostate cancer | $459K | PROGENICS PHARMACEUTICALS INC |
| Sep 30, 2002 | NIH | SBIR/STTR Phase II PSMA-VRP vaccine for prostate cancer | $575K | PROGENICS PHARMACEUTICALS INC |
| Sep 1, 2001 | NIH | SBIR/STTR Phase I Development of Small-Molecule HIV Entry Inhibitors | $300K | PROGENICS PHARMACEUTICALS INC |
| Sep 1, 2001 | NIH | SBIR/STTR Phase II Development of Small-Molecule HIV Entry Inhibitors | $833K | PROGENICS PHARMACEUTICALS INC |
| Sep 1, 2001 | NIH | SBIR/STTR Phase I CCR5 Sulfopeptides:A New Class of HIV Entry Inhibitors | $300K | PROGENICS PHARMACEUTICALS INC |
| Sep 15, 2000 | NIH | SBIR/STTR Phase II Humanized PRO 140 for CCR5-Targeted Therapy of HIV | $1.1M | PROGENICS PHARMACEUTICALS INC |
| Sep 15, 2000 | NIH | SBIR/STTR Phase II Humanized PRO 140 for CCR5-Targeted Therapy of HIV | $924K | PROGENICS PHARMACEUTICALS INC |
| Sep 15, 2000 | NIH | SBIR/STTR Phase I PA 14 CORECEPTOR-TARGETED IMMUNOTHERAPY OF HIV INFECTION | $300K | PROGENICS PHARMACEUTICALS INC |
| Sep 15, 2000 | NIH | SBIR/STTR Phase II Humanized PRO 140 for CCR5-Targeted Therapy of HIV | $1.0M | PROGENICS PHARMACEUTICALS INC |
| Sep 1, 2000 | NIH | SBIR/STTR Phase II Transgenic Production of CD4-IgG2 for HIV Therapy | $640K | PROGENICS PHARMACEUTICALS INC |
| Sep 1, 2000 | NIH | SBIR/STTR Phase II Transgenic Production of CD4-IgG2 for HIV Therapy | $1.0M | PROGENICS PHARMACEUTICALS INC |
| Sep 1, 2000 | NIH | SBIR/STTR Phase I TRANSGENIC PRODUCTION OF CD4-IGG2 FOR HIV THERAPY | $300K | PROGENICS PHARMACEUTICALS INC |
| Sep 1, 2000 | NIH | SBIR/STTR Phase II Transgenic Production of CD4-IgG2 for HIV Therapy | $1.0M | PROGENICS PHARMACEUTICALS INC |
Peer ranks
Federal funding#6
Awards as PI#7
Patents#27
Companies
- PROGENICS PHARMACEUTICALS INCLinked by awards
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.